Evidence map›Paper›PMID 39208372›Full record

ArticleJCO precision oncology2024

Pharmacodynamic Activity of [

Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Yap, Jennifer K Litton

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Lilie L LinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7681-8966
Franklin WongDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2244-131X
Timothy YapDepartment of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2154-3309
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8390-4985

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
A novel PARP inhibitor PET tracer for breast cancerR01CA249329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, LILIE LEMING, PIWNICA-WORMS, DAVID · 2021 to 2023
$748k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA249329
6 · The paper itself

Abstract

purposeWe tested the ability of [

methodsSeven patients with germline

resultsBlocking of [

conclusionWe conclude that [

Indexed as

Breast NeoplasmsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedBRCA1 ProteinBRCA2 ProteinFemaleFluorine RadioisotopesHumansMiddle AgedMutationPositron-Emission TomographyPositron Emission Tomography Computed TomographyBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanFluorine RadioisotopesPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparib

Identifiers

PMID39208372
PMCPMC12158472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.